<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Collections &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/collections/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Comprehensive care program does not prevent COPD hospitalizations</title>
		<link>http://www.thedoctorschannel.com/view/comprehensive-care-program-does-not-prevent-copd-hospitalizations/</link>
		<pubDate>Wed, 16 May 2012 15:30:24 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Home Page Featured]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pulmonary Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[SHM 2011 Conference Coverage]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[education]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31828</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A program of patient education and planning aimed at treating exacerbations of chronic obstructive pulmonary disease early and reducing rates of hospitalization was not effective in a randomized controlled trial. In fact, the trial was stopped when it was seen that the intervention was associated with a threefold increase in -]]></description>
		
			<media:content duration="1:38" medium="video">
		<media:title><![CDATA[Comprehensive care program does not prevent COPD hospitalizations]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A program of patient education and planning aimed at treating exacerbations of chronic obstructive pulmonary disease early and reducing rates of hospitalization was not effective in a randomized controlled trial. In fact, the trial was stopped when it was seen that the intervention was associated with a threefold increase in -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/comprehensive-care-program-does-not-prevent-copd-hospitalizations/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120516clin002.jpg"/>
	<media:keywords><![CDATA[COPD,education]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Rocket AF Brief Overview</title>
		<link>http://www.thedoctorschannel.com/view/rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-brief-overview/</link>
		<pubDate>Tue, 01 May 2012 20:43:21 +0000</pubDate> 
				<category><![CDATA[Featured Information from Industry]]></category>
		<category><![CDATA[vPrint Library: ROCKET AF Results]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31029</guid>
		<description><![CDATA[Presented by Bruce Stambler, MD An overview of the ROCKET AF trial, which compared once-daily XARELTO® to dose-adjusted warfarin in patients with nonvalvular atrial fibrillation. This multinational trial involved more than 14,000 patients with atrial fibrillation (AF) and moderate-to-high stroke risk (mean CHADS2 score 3.5). It concluded that XARELTO® was noninferior to warfarin for reducing -]]></description>
		
			<media:content duration="4:35" medium="video">
		<media:title><![CDATA[Rocket AF Brief Overview]]></media:title>
	<media:description><![CDATA[Presented by Bruce Stambler, MD An overview of the ROCKET AF trial, which compared once-daily XARELTO® to dose-adjusted warfarin in patients with nonvalvular atrial fibrillation. This multinational trial involved more than 14,000 patients with atrial fibrillation (AF) and moderate-to-high stroke risk (mean CHADS2 score 3.5). It concluded that XARELTO® was noninferior to warfarin for reducing -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-brief-overview/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/vprint-thumbnail.jpeg"/>
	<media:keywords><![CDATA[]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Rocket AF Clinical Implications</title>
		<link>http://www.thedoctorschannel.com/view/rivaroxaban-vs-warfarin-in-nonvalvular-atrial-fibrillation-clinical-implications/</link>
		<pubDate>Tue, 01 May 2012 20:43:08 +0000</pubDate> 
				<category><![CDATA[vPrint Library: ROCKET AF Results]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31062</guid>
		<description><![CDATA[Presented by Bruce Stambler, MD The large, multinational ROCKET AF trial found the select Factor Xa inhibitor, XARELTO&#174;, to be noninferior to warfarin in preventing stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. Previous videos in this series discussed the trial&#8217;s design and findings. This video looks at -]]></description>
		
			<media:content duration="7:57" medium="video">
		<media:title><![CDATA[Rocket AF Clinical Implications]]></media:title>
	<media:description><![CDATA[Presented by Bruce Stambler, MD The large, multinational ROCKET AF trial found the select Factor Xa inhibitor, XARELTO&#174;, to be noninferior to warfarin in preventing stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. Previous videos in this series discussed the trial&#8217;s design and findings. This video looks at -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/rivaroxaban-vs-warfarin-in-nonvalvular-atrial-fibrillation-clinical-implications/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/vprint-thumbnail.jpeg"/>
	<media:keywords><![CDATA[]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Rocket AF Trial Design</title>
		<link>http://www.thedoctorschannel.com/view/rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-trial-design/</link>
		<pubDate>Tue, 01 May 2012 20:42:56 +0000</pubDate> 
				<category><![CDATA[vPrint Library: ROCKET AF Results]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31050</guid>
		<description><![CDATA[Presented by Bruce Stambler, MD The multinational ROCKET AF trial compared XARELTO&#174; to warfarin in more than 14,000 patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. It established that XARELTO&#174; is noninferior to warfarin for reducing the risk of stroke and embolism in these patients. Superiority of XARELTO&#174; was not established. This report looks -]]></description>
		
			<media:content duration="3:42" medium="video">
		<media:title><![CDATA[Rocket AF Trial Design]]></media:title>
	<media:description><![CDATA[Presented by Bruce Stambler, MD The multinational ROCKET AF trial compared XARELTO&#174; to warfarin in more than 14,000 patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. It established that XARELTO&#174; is noninferior to warfarin for reducing the risk of stroke and embolism in these patients. Superiority of XARELTO&#174; was not established. This report looks -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-trial-design/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/vprint-thumbnail.jpeg"/>
	<media:keywords><![CDATA[]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Rocket AF Trial Results</title>
		<link>http://www.thedoctorschannel.com/view/rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-trial-results/</link>
		<pubDate>Tue, 01 May 2012 20:42:42 +0000</pubDate> 
				<category><![CDATA[vPrint Library: ROCKET AF Results]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31056</guid>
		<description><![CDATA[Presented by Bruce Stambler, MD The multinational ROCKET AF trial compared XARELTO&#174; to warfarin in more than 14,000 patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. It demonstrated that XARELTO&#174; was noninferior to warfarin for reducing the risk of stroke and embolism in these patients. Superiority of XARELTO&#174; was not established. This report looks -]]></description>
		
			<media:content duration="3:18" medium="video">
		<media:title><![CDATA[Rocket AF Trial Results]]></media:title>
	<media:description><![CDATA[Presented by Bruce Stambler, MD The multinational ROCKET AF trial compared XARELTO&#174; to warfarin in more than 14,000 patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. It demonstrated that XARELTO&#174; was noninferior to warfarin for reducing the risk of stroke and embolism in these patients. Superiority of XARELTO&#174; was not established. This report looks -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-trial-results/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/vprint-thumbnail.jpeg"/>
	<media:keywords><![CDATA[]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Reading Minds through Neuroimaging</title>
		<link>http://www.thedoctorschannel.com/view/reading-minds-through-neuroimaging/</link>
		<pubDate>Tue, 10 Apr 2012 22:37:37 +0000</pubDate> 
				<category><![CDATA[FutureMed 2012 Conference]]></category>
		<category><![CDATA[de Charms]]></category>
		<category><![CDATA[FutureMed]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[Neuroimaging]]></category>
		<category><![CDATA[Singularity University]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27801</guid>
		<description><![CDATA[Christopher deCharms, MD, Founder &#038; CEO, Omneuron, explains that recent advances allow the &#8220;reading&#8221; of thoughts directly from the brain via functional MRI and other technologies. Filmed at FutureMed, in February, 2012, at Singularity University.]]></description>
		
			<media:content duration="1:39" medium="video">
		<media:title><![CDATA[Reading Minds through Neuroimaging]]></media:title>
	<media:description><![CDATA[Christopher deCharms, MD, Founder &#038; CEO, Omneuron, explains that recent advances allow the &#8220;reading&#8221; of thoughts directly from the brain via functional MRI and other technologies. Filmed at FutureMed, in February, 2012, at Singularity University.]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/reading-minds-through-neuroimaging/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Screen-shot-2012-04-10-at-10.58.05-AM.png"/>
	<media:keywords><![CDATA[de Charms,FutureMed,genomics,Neuroimaging,Singularity University]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Is Aging an Inevitable Process?</title>
		<link>http://www.thedoctorschannel.com/view/is-aging-an-inevitable-process/</link>
		<pubDate>Tue, 10 Apr 2012 22:35:46 +0000</pubDate> 
				<category><![CDATA[FutureMed 2012 Conference]]></category>
		<category><![CDATA[aging]]></category>
		<category><![CDATA[de Grey]]></category>
		<category><![CDATA[FutureMed]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[SENS Founation]]></category>
		<category><![CDATA[Singularity University]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27806</guid>
		<description><![CDATA[Aubrey de Grey, MA, PhD, Chief Science Officer, SENS Foundation, offers a definition of aging that refocuses the question of whether or not it is an inevitable process. Filmed at FutureMed, in February, 2012, at Singularity University.]]></description>
		
			<media:content duration="3:04" medium="video">
		<media:title><![CDATA[Is Aging an Inevitable Process?]]></media:title>
	<media:description><![CDATA[Aubrey de Grey, MA, PhD, Chief Science Officer, SENS Foundation, offers a definition of aging that refocuses the question of whether or not it is an inevitable process. Filmed at FutureMed, in February, 2012, at Singularity University.]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/is-aging-an-inevitable-process/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Screen-shot-2012-04-10-at-6.32.38-PM.png"/>
	<media:keywords><![CDATA[aging,de Grey,FutureMed,genomics,SENS Founation,Singularity University]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Workflow Management and Patient Engagement</title>
		<link>http://www.thedoctorschannel.com/view/workflow-management-and-patient-engagement/</link>
		<pubDate>Tue, 10 Apr 2012 22:30:40 +0000</pubDate> 
				<category><![CDATA[FutureMed 2012 Conference]]></category>
		<category><![CDATA[DeGheest]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[Workflow management]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27809</guid>
		<description><![CDATA[Anne Degheest, Managing Director &#038; Founder, HealthTech CAPITAL, offers advice to entrepreneurs developing solutions for medical workflow management and patient engagement. Filmed at FutureMed, in February, 2012, at Singularity University.]]></description>
		
			<media:content duration="3:34" medium="video">
		<media:title><![CDATA[Workflow Management and Patient Engagement]]></media:title>
	<media:description><![CDATA[Anne Degheest, Managing Director &#038; Founder, HealthTech CAPITAL, offers advice to entrepreneurs developing solutions for medical workflow management and patient engagement. Filmed at FutureMed, in February, 2012, at Singularity University.]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/workflow-management-and-patient-engagement/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Screen-shot-2012-04-10-at-6.26.58-PM.png"/>
	<media:keywords><![CDATA[DeGheest,genomics,Workflow management]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>The Experimental Man Project</title>
		<link>http://www.thedoctorschannel.com/view/the-experimental-man-project/</link>
		<pubDate>Tue, 10 Apr 2012 22:27:01 +0000</pubDate> 
				<category><![CDATA[FutureMed 2012 Conference]]></category>
		<category><![CDATA[Experimental man]]></category>
		<category><![CDATA[FutureMed]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[Singularity University]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27811</guid>
		<description><![CDATA[Journalist David Ewing Duncan, discusses his personal experiences with the technologies of personalized medicine, and touches on the implications of genomics, proteomics, metabolomics and microbiomics. Filmed at FutureMed, in February, 2012, at Singularity University.]]></description>
		
			<media:content duration="3:13" medium="video">
		<media:title><![CDATA[The Experimental Man Project]]></media:title>
	<media:description><![CDATA[Journalist David Ewing Duncan, discusses his personal experiences with the technologies of personalized medicine, and touches on the implications of genomics, proteomics, metabolomics and microbiomics. Filmed at FutureMed, in February, 2012, at Singularity University.]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/the-experimental-man-project/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Screen-shot-2012-04-10-at-11.12.02-AM.png"/>
	<media:keywords><![CDATA[Experimental man,FutureMed,personalized medicine,Singularity University]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Technology&#8217;s Role in Humanitarian Aid</title>
		<link>http://www.thedoctorschannel.com/view/technologys-role-in-humanitarian-aid/</link>
		<pubDate>Tue, 10 Apr 2012 22:24:22 +0000</pubDate> 
				<category><![CDATA[FutureMed 2012 Conference]]></category>
		<category><![CDATA[Fink]]></category>
		<category><![CDATA[FutureMed]]></category>
		<category><![CDATA[Humanitarian aid]]></category>
		<category><![CDATA[Singularity University]]></category>
		<category><![CDATA[Stanford University]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27816</guid>
		<description><![CDATA[Sheri Fink, MD, PhD, Senior Fellow, New America Foundation, discusses the role that technology can, and should, play in organizing and managing humanitarian aid efforts. Filmed at FutureMed, in February, 2012, at Singularity University.]]></description>
		
			<media:content duration="3:40" medium="video">
		<media:title><![CDATA[Technology&#8217;s Role in Humanitarian Aid]]></media:title>
	<media:description><![CDATA[Sheri Fink, MD, PhD, Senior Fellow, New America Foundation, discusses the role that technology can, and should, play in organizing and managing humanitarian aid efforts. Filmed at FutureMed, in February, 2012, at Singularity University.]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/technologys-role-in-humanitarian-aid/collection/collection-collections" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Screen-shot-2012-04-10-at-6.20.28-PM.png"/>
	<media:keywords><![CDATA[Fink,FutureMed,Humanitarian aid,Singularity University,Stanford University]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
